Is Egrifta (Tesamorelin) Legal in Michigan?

What Is Tesamorelin and Why Does Legal Status Matter?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce endogenous growth hormone. The FDA approved the branded formulation Egrifta in August 2010 under NDA 022505, specifically for reducing excess abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. [1] A reformulated version, Egrifta SV, received approval in 2019. [2]

Legal status matters for two distinct reasons. First, patients and providers need to know whether a prescription can be written and filled inside Michigan without any additional state-level permit. Second, the rise of compounding pharmacies offering tesamorelin for off-label uses (anti-aging, body composition, athlete recovery) has created a gray area that requires careful navigation.

The Core Legal Question: Federal Approval vs. State Law

Michigan does not operate a parallel drug-approval system. The Michigan Public Health Code (Act 368 of 1978) defers to federal FDA approval as the threshold for lawful dispensing of prescription drugs. Because tesamorelin is an FDA-approved prescription drug, the baseline answer for Michigan residents is straightforward: legal with a prescription.

Why Some Peptides Are in a Gray Area While Tesamorelin Is Not

Peptides such as BPC-157, TB-500, or CJC-1295 lack FDA approval entirely and appear on the FDA's list of bulk drug substances that may not be used in compounding. [3] Tesamorelin does not share that status. It is an approved new drug application (NDA) product, which places it in a fundamentally different regulatory category from unapproved research peptides.

Federal Regulatory Framework Governing Tesamorelin

FDA Approval and the NDA Record

The FDA's approval of tesamorelin under NDA 022505 established efficacy and safety data from two randomized, double-blind, placebo-controlled Phase 3 trials. In the key LIPO trial (N=412), tesamorelin 2 mg/day subcutaneously reduced visceral adipose tissue by a mean of 18% at 26 weeks compared with 5% in the placebo group (P<0.001). [4] The FDA's labeling also specifies contraindications: active malignancy, disruption of the hypothalamic-pituitary axis, and pregnancy. [1]

Because the product is approved under an NDA, it is a "listed drug" in FDA's Orange Book. [5] This matters for compounding law, as discussed below.

DEA Scheduling: Not a Controlled Substance

The Drug Enforcement Administration does not schedule tesamorelin under the Controlled Substances Act (21 U.S.C. § 812). [6] Unlike testosterone, anabolic steroids, or HGH (somatropin) itself (which is a Schedule III controlled substance), tesamorelin as a GHRH analog occupies no schedule. Prescribers in Michigan therefore need no DEA special registration to prescribe it, and patients need no separate controlled-substance prescription form.

503A and 503B Compounding Rules

This is where tesamorelin's legal field becomes more nuanced.

503A pharmacies (traditional compounding for individual patients) may compound tesamorelin under a valid prescription, provided the compounded preparation is not essentially a copy of the commercially available Egrifta SV and the pharmacy complies with USP standards. The FDA has not placed tesamorelin on its "Demonstrably Difficult to Compound" list, nor on the list of bulk substances prohibited for 503A use. [3] A 503A pharmacy may therefore compound tesamorelin with a patient-specific prescription.

503B outsourcing facilities operate differently. Because tesamorelin is an FDA-approved drug, a 503B facility may compound it only if the drug appears on the FDA's 503B Bulks List, or if the facility is producing it for hospital/clinic use not as a copy of the approved product. As of the date of this article, tesamorelin has not appeared on the final 503B Bulks List. [7] Patients sourcing tesamorelin from a 503B facility should confirm that facility's specific FDA registration and compliance status.

Michigan-Specific Legal Framework

Michigan Public Health Code and Pharmacy Act

Michigan's pharmacy licensing and practice rules fall under the Michigan Public Health Code, Act 368 of 1978, and are administered by the Michigan Department of Licensing and Regulatory Affairs (LARA) and the Michigan Board of Pharmacy. Michigan has not enacted any separate statute that restricts tesamorelin beyond what federal law requires. A prescription from a Michigan-licensed prescriber is sufficient for a Michigan-licensed pharmacy to dispense brand Egrifta SV.

The Michigan Board of Pharmacy regulates compounding pharmacies operating within state borders and requires compliance with federal USP standards (USP 795 for non-sterile and USP 797 for sterile preparations). Tesamorelin is an injectable peptide, so any Michigan compounding pharmacy preparing it must meet USP 797 sterile compounding standards. [8]

Michigan Controlled Substances Act

Michigan's Controlled Substances Act (MCL 333.7101 et seq.) lists substances across Schedules 1 through 5. Tesamorelin does not appear on any Michigan schedule. [9] Because it is not scheduled at the state level, it is treated as a standard prescription-only drug in Michigan, not subject to triplicate forms, quantity limits per prescription, or the 30-day dispensing restrictions that apply to Schedule 2 drugs.

Telehealth Prescribing in Michigan

Michigan's telehealth statute (MCL 333.16285) allows licensed prescribers to establish a valid patient-prescriber relationship via synchronous audio-video interaction and then issue prescriptions, including for non-controlled drugs like tesamorelin. [10] The Michigan Medical Board has not issued a special exclusion for peptides. This means a Michigan patient can receive a tesamorelin prescription through a licensed telehealth platform without an in-person visit, provided the prescriber conducts a thorough history, reviews relevant labs (IGF-1, fasting glucose, HbA1c), and documents clinical justification.

Off-Label Prescribing

FDA approval of Egrifta covers HIV-associated lipodystrophy. Prescribers in Michigan, as in all U.S. States, retain the legal right to prescribe approved drugs off-label when medical judgment supports it. The American Academy of Family Physicians' position on off-label prescribing confirms that physicians may prescribe approved drugs for unapproved indications based on peer-reviewed evidence and clinical judgment. [11] Off-label tesamorelin use (for example, in non-HIV patients with visceral adiposity or growth hormone deficiency) is therefore a legal prescribing act in Michigan, though it may affect insurance reimbursement.

How to Get a Legal Tesamorelin Prescription in Michigan

Step 1: Establish a Prescriber Relationship

The first step is a consultation with a Michigan-licensed physician, DO, nurse practitioner, or physician assistant who holds prescriptive authority. The prescriber must take a medical history, review current medications, and assess for contraindications including active cancer, pituitary pathology, or pregnancy.

Step 2: Baseline Laboratory Work

Before initiating tesamorelin, clinicians typically order:

• Fasting serum IGF-1 (to establish baseline and monitor for supraphysiologic elevation)
• Fasting glucose and HbA1c (tesamorelin may reduce insulin sensitivity; the FDA label notes glucose intolerance as an adverse effect) [1]
• Lipid panel (visceral fat reduction may improve but not normalize lipids)
• HIV status if prescribing for labeled indication

Step 3: Pharmacy Selection

Patients in Michigan have three lawful options:

1. A licensed Michigan retail or specialty pharmacy dispensing brand Egrifta SV (2 mg/vial) under NDA 022505.
2. A Michigan-licensed 503A compounding pharmacy that prepares patient-specific tesamorelin preparations under a valid prescription, compliant with USP 797.
3. An out-of-state 503A or accredited 503B facility that ships to Michigan, provided the facility holds the necessary state-of-origin pharmacy license and Michigan allows out-of-state compounding pharmacy registration under Michigan Board of Pharmacy rules.

Step 4: Telehealth Options

Several national telehealth platforms hold prescriber licensure in Michigan and can support a tesamorelin consultation, lab order, and prescription entirely remotely. Michigan law requires the prescriber to be licensed in Michigan and to conduct the encounter via synchronous audio-video, not asynchronous messaging alone, for an initial prescription of this type. [10]

Safety and Clinical Considerations

Efficacy Data From Published Trials

The legal status of tesamorelin is supported by a strong clinical evidence base. The key trials submitted to the FDA enrolled HIV-positive adults with confirmed lipodystrophy. In a pooled analysis of two Phase 3 trials (combined N=816), tesamorelin 2 mg/day subcutaneously reduced visceral adipose tissue (VAT) by 18.1% from baseline at 26 weeks, versus a 5.0% reduction with placebo. [4] Triglyceride levels fell by approximately 50 mg/dL in the tesamorelin arm at 26 weeks. [4]

The FDA's medical officer review noted that IGF-1 levels rose above the upper limit of normal in approximately 40% of treated patients during the trials, which is why monitoring is a standard-of-care expectation. [1]

Known Adverse Effects Affecting Prescribing Decisions

Tesamorelin carries a class effect risk related to glucose metabolism. The FDA-approved prescribing information states that tesamorelin may cause glucose intolerance, and the drug is contraindicated in patients with active malignancy due to theoretical IGF-1-mediated growth stimulation. [1] Patients with pre-diabetes should have HbA1c rechecked at 3 months. The prescribing information also warns against use in patients with active Cushing's syndrome or receiving glucocorticoid therapy for hypopituitarism, as the drug would have no pituitary substrate to act on. [1]

Monitoring Schedule

Most clinical protocols adapted from the FDA label recommend:

• IGF-1 recheck at 3 months; dose adjustment or discontinuation if values exceed 2 standard deviations above age-adjusted norms
• Fasting glucose at 3 and 6 months
• Clinical assessment of VAT reduction (waist circumference or DEXA/CT imaging) at 6 months to assess response

The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults states that IGF-1 monitoring is the standard biochemical endpoint for any GHRH or GH-axis therapy. [12]

Insurance, Cost, and Access Realities in Michigan

Brand Egrifta SV Coverage

Medicaid and private insurers in Michigan cover Egrifta SV for the FDA-labeled HIV lipodystrophy indication. Off-label prescriptions are rarely covered by commercial plans and essentially never covered by Medicaid without a labeled diagnosis. The manufacturer (Theratechnologies) operates a patient assistance program; prescribers can access it through the manufacturer's registered support portal. [2]

Compounded Tesamorelin Cost

Compounded tesamorelin from a 503A pharmacy typically costs between $150 and $400 per month depending on dose and concentration. These preparations are not covered by insurance. Patients choosing the compounding route to access off-label use accept that they are receiving a non-FDA-approved preparation and should confirm that the compounding pharmacy holds current PCAB accreditation or equivalent state board certification.

What Is Not Legal: Key Boundaries

Three specific scenarios cross the legal line in Michigan and nationally:

1. Purchasing tesamorelin from an international or online vendor without a U.S. Prescription. This violates 21 U.S.C. § 331 (prohibited acts under the Federal Food, Drug, and Cosmetic Act) and potentially Michigan MCL 333.7401. [6]
2. A 503A pharmacy providing tesamorelin without a patient-specific prescription. Section 503A of the FD&C Act requires a valid prescription for compounded drugs. Dispensing without one removes the 503A exemption and makes the drug an unapproved new drug in interstate commerce. [3]
3. Obtaining tesamorelin under a fraudulent diagnosis. Falsifying a lipodystrophy diagnosis to obtain insurance coverage for off-label use is healthcare fraud under 18 U.S.C. § 1347 and Michigan's health care fraud statute (MCL 752.1003).

Frequently Asked Questions